LIVMARLI® Global Availability

The first approved treatment for cholestatic pruritus in patients with Alagille syndrome (ALGS) globally. See where LIVMARLI is now approved.*

*Approval through country regulatory agencies; commercialized by Mirum or partner/distributor.

United States

Cholestatic pruritus in ALGS three months and older

Prescribing Information and Important Safety Information

European Union

Cholestatic pruritus in ALGS two months and older

SMPC

Canada

Cholestatic pruritus in ALGS

• Pediatrics (12 months to 18 years): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of LIVMARLI in these pediatric patients have been established. Therefore, Health Canada has authorized an indication for pediatric use.
• Pediatrics (<12 months): The safety and efficacy of LIVMARLI in these pediatric patients have not been established.

Product Monograph

China¹

Cholestatic pruritus in ALGS one year
and older

Israel²

Cholestatic pruritus in ALGS one year
and older

South Korea³

Cholestatic pruritus in ALGS one year
and older

1. Approved through country regulatory agencies; commercialized by partner, CANbridge.

2. Approved through country regulatory agencies; commercialized by distributor partner, Neopharm.

3. Approved through country regulatory agencies; commercialized by partner, GC Pharma.